Delcath Systems, Inc. (DCTH)
$
11.02
+0.14 (1.27%)
Key metrics
Financial statements
Free cash flow per share
0.1081
Market cap
385.5 Million
Price to sales ratio
8.6737
Debt to equity
0.0095
Current ratio
10.8751
Income quality
2.1729
Average inventory
8.8 Million
ROE
0.0340
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Delcath Systems, Inc., an interventional oncology company specializing in the treatment of primary and metastatic liver cancers in the U.S. and Europe, reported a net total of other income and expenses of -$13,976,000.00 reflecting its non-core financial activities. The company incurred an interest expense of $0.00 highlighting its debt servicing obligations. Its operating expenses amounted to $43,427,000.00 encompassing a variety of operational costs the company has incurred throughout its fiscal activities. Delcath achieved a revenue of $37,205,000.00 underscoring its focus on a niche market within the oncology therapeutic landscape. Furthermore, the earnings per share (EPS) is reported at -$0.93 indicating the company's profitability on a per-share basis and demonstrating its financial performance amidst its specialized operational focus. The clinical development program for its lead product candidate, HEPZATO KIT, involves the FOCUS clinical trial targeting metastatic hepatic dominant Uveal Melanoma to assess the objective response rate, while also offering HEPZATO as the standalone CHEMOSAT Hepatic Delivery System in Europe for various liver cancer treatments. In terms of investment perspective, the stock is affordable at $11.87 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 754,212.00 indicating lower market activity that might affect liquidity. Delcath’s market capitalization stands at $385,493,926.00 classifying the company as a small-cap player within the broader financial arena. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape with its innovative approaches to cancer treatment. Additionally, it belongs to the Healthcare sector, driving not only its own growth but also fostering advancements that may benefit the healthcare industry as a whole.
Is Delcath Systems, Inc. (DCTH) a good investment?
Investing in Delcath Systems, Inc. (DCTH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Delcath Systems, Inc. (DCTH)'s stock forecast?
Analysts predict Delcath Systems, Inc. stock to fluctuate between $8.08 (low) and $18.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Delcath Systems, Inc.'s market capitalization?
As of 2025-08-29, Delcath Systems, Inc.'s market cap is $385,493,926, based on 34,981,300 outstanding shares.
How does Delcath Systems, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Delcath Systems, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Delcath Systems, Inc. (DCTH) stock?
To buy Delcath Systems, Inc. (DCTH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DCTH. Place an order (Market, Limit, etc.).
What is the best time to invest in Delcath Systems, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Delcath Systems, Inc. stock ever split?
Delcath Systems, Inc.'s last stock split was 1:700 on 2019-12-27.
How did Delcath Systems, Inc. perform in the last earnings report?
Revenue: $37,205,000 | EPS: -$0.93 | Growth: -68.37%.
Where can I find Delcath Systems, Inc.'s investor relations reports?
Visit https://www.delcath.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Delcath Systems, Inc.?
You can explore historical data from here
What is the all-time high and low for Delcath Systems, Inc. stock?
All-time high: $18.23 (2025-05-20) | All-time low: $2.25 (2023-11-14).
What are the key trends affecting Delcath Systems, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the City of Hope National Medical Center in its global Phase 2 Clinical Trial evaluating HEPZATO™ in combination with standard of care (SOC) treatment for liver-dominant metastatic colorectal cancer (mCRC). The Phase 2 trial will evaluate the safety and efficacy of HE.
seekingalpha.com
Delcath Systems, Inc. (NASDAQ:DCTH ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard J. Michel - CEO & Director Kevin Muir - Corporate Participant Sandra Pennell - Chief Financial Officer Vojislav Vukovic - Chief Medical Officer Conference Call Participants Bill Morgan - Unidentified Company Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division I-Eh Jen - Laidlaw & Company (UK) Ltd.
zacks.com
Investors need to pay close attention to DCTH stock based on the movements in the options market lately.
seekingalpha.com
Delcath's HEPZATO shows rapid sales growth and high pricing, but its efficacy is only moderately better than alternatives and not curative. The addressable market is small, treatment is complex, and future competition from Replimune or Ideaya could threaten long-term prospects and valuation multiples. Financials are solid with no debt, recent profitability, and reasonable stock-based compensation; forward P/S ratio is attractive versus peers.
zacks.com
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
businesswire.com
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025 at The Depot Renaissance Hotel in Minneapolis, MN. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of.
zacks.com
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.43 per share a year ago.
businesswire.com
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in th.
businesswire.com
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO™ in combination with standard of care (SOC) for liver-dominant metastatic breast cancer (mBC). With the FDA's review com.
businesswire.com
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a comparative analysis from the randomized cohort of the Company's Phase 3 FOCUS study in Annals of Surgical Oncology. The study, titled “An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanom.
See all news
